NT 1 - NanotargetingAlternative Names: Aurocis; NT1 - Nanotargeting
Latest Information Update: 18 Jul 2016
At a glance
- Originator Nanotargeting
- Developer Ferrer; Nanotargeting
- Class Platinum complexes
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Jul 2016 Preclinical trials in Cancer in Spain (Parenteral)